PARP16 protects against pathological cardiac remodelling by ADP-ribosylation-dependent inhibition of NFAT transcription factor
Curation statements for this article:-
Curated by eLife
eLife Assessment
The study presents valuable findings on PARP16, a regulator of pathological cardiac remodelling, by providing novel mechanistic insights and potential therapeutic targets for heart failure. The data are mainly solid; however, there are also incomplete data relating to the in vivo analyses, biochemical assays and imaging data analyses and evidence supporting direct ADP-ribosylation. The work will be of interest to cell biologists and clinicians in cardiovascular disease.
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (eLife)
Abstract
Mono-ADP-ribosylation is a post-translational modification that regulates diverse cellular processes. PARP16 is an endoplasmic reticulum-associated mono-ADP-ribosyltransferase implicated in stress-response signalling; however, its role in cardiac remodelling and dysfunction has not been fully defined. Our results suggest that PARP16 expression was reduced in human heart failure samples. Deletion of PARP16 in several mice models promoted ventricular dilatation, fibrosis, fetal gene reactivation, and systolic dysfunction, whereas cardiomyocyte-specific overexpression of PARP16 attenuated isoproterenol-induced remodelling in mice. Transcriptomic profiling and functional studies identified NFAT signalling as a major downstream pathway activated following PARP16 deficiency. Specifically, loss of PARP16 increased nuclear accumulation, promoter occupancy, and transcriptional activity of NFAT1. Mechanistically, PARP16 interacted with NFAT1 and suppressed NFAT-dependent transcription through a catalytic activity-dependent mechanism. Proteomic, structural, and functional analyses identified E398 and T533 residues of NFAT1 associated with PARP16-mediated regulation. Furthermore, pharmacological inhibition of NFAT improved cardiac function and remodelling in PARP16-deficient mice. These findings indicate that PARP16 acts as a negative regulator of NFAT signalling and contributes to protection against adverse cardiac remodelling.
Article activity feed
-
eLife Assessment
The study presents valuable findings on PARP16, a regulator of pathological cardiac remodelling, by providing novel mechanistic insights and potential therapeutic targets for heart failure. The data are mainly solid; however, there are also incomplete data relating to the in vivo analyses, biochemical assays and imaging data analyses and evidence supporting direct ADP-ribosylation. The work will be of interest to cell biologists and clinicians in cardiovascular disease.
-
Reviewer #1 (Public review):
This study identifies a novel PARP16-NFAT1 signaling axis that attenuates pathological cardiac remodeling, supported by strong, multi-dimensional evidence from genetic mouse models, transcriptomics, ChIP-qPCR, and molecular dynamics simulations. The findings are mechanistically novel and offer potential therapeutic targets for heart failure, though several methodological and reporting issues require further clarification and revision.
This manuscript demonstrated that PARP16 expression is significantly downregulated in cardiac tissues from heart failure patients. Using whole-body, cardiomyocyte-specific, inducible cardiomyocyte-specific PARP16 knockout and overexpression mouse models, the authors confirmed that PARP16 effectively attenuates adverse cardiac remodeling and improves cardiac function. …
Reviewer #1 (Public review):
This study identifies a novel PARP16-NFAT1 signaling axis that attenuates pathological cardiac remodeling, supported by strong, multi-dimensional evidence from genetic mouse models, transcriptomics, ChIP-qPCR, and molecular dynamics simulations. The findings are mechanistically novel and offer potential therapeutic targets for heart failure, though several methodological and reporting issues require further clarification and revision.
This manuscript demonstrated that PARP16 expression is significantly downregulated in cardiac tissues from heart failure patients. Using whole-body, cardiomyocyte-specific, inducible cardiomyocyte-specific PARP16 knockout and overexpression mouse models, the authors confirmed that PARP16 effectively attenuates adverse cardiac remodeling and improves cardiac function. Mechanistically, the authors integrated multiple experimental approaches, including transcriptome sequencing, ChIP-qPCR, PARP16 knockout and transgenic mouse model generation, and all-atom molecular dynamics simulations. They revealed that PARP16 mediates ADP-ribosylation of NFAT1 in a catalytic activity-dependent manner, restrains nuclear accumulation and transcriptional activation of NFAT1, and defines a novel PARP16-NFAT1 signaling axis that modulates pathological cardiac remodeling. Overall, this study is well designed, and the multi-dimensional experimental evidence strongly supports the core scientific hypothesis. The findings provide novel mechanistic insights and potential therapeutic targets for heart failure.
However, several aspects require further optimization, supplementation, and clarification to be improved.
(1) There are mismatches between figure citations and graphical results. The authors should carefully check and revise relevant figures, including Figure 6BCEF and Figure 8CD.
(2) For Figure 1CD, the original high-definition images, detailed statistical workflows, and raw quantitative data regarding PARP16 expression in human failing hearts should be provided.
(3) The study used ANP, BNP, α-MHC, and β-MHC as hallmark biomarkers of heart failure. The biological significance and rationale of these indicators should be briefly introduced in the manuscript.
(4) Redundant phenotypic results are observed in Figure 3B/C, Figure 4C/D, and Figure 5B/C. The authors are suggested to retain Figure 3B, Figure 4C, and Figure 5B, supplement quantitative statistical analysis of protein expression levels, and provide all high-definition images and complete statistical datasets.
(5) In lines 313-321, the authors discussed inconsistent conclusions between the present study and reference 16 and attributed the discrepancies to different disease models and experimental approaches. Does this mean that the disease model and approaches in the article are unreliable? Has any related validation been conducted in this model? The mRNA and protein expression levels of key molecules in the IRE1α-sXBP1-GATA4 signaling pathway should be detected and validated.
(6) The official ethical approval document (HEC No: 06/22.06.2023) and written informed consent documents for human sample collection must be submitted.
(7) Typographical errors should be corrected throughout the manuscript, such as the incorrect word "hypertrophy" (line 100).
(8) To validate the successful construction of genetically modified mice and ensure the reliability of subsequent phenotypic and mechanistic data, the authors need to supplement detailed genotyping primer sequences, representative agarose gel electrophoresis images, and complete genotyping statistical results.
Addressing the above-mentioned issues will significantly improve the quality, rigor, and readability of this work.
-
Reviewer #2 (Public review):
In this study, the authors investigate the role of PARP16, an ER-resident mono-ADP-ribosyltransferase, in the heart. To address this, they generate a set of complementary mouse models: whole-body Parp16 knockout mice, constitutive and tamoxifen-inducible cardiomyocyte-specific knockout mice, and cardiomyocyte-specific transgenic mice overexpressing PARP16. Using these models, they show that loss of PARP16 causes pathological cardiac remodeling, whereas its overexpression protects the heart from isoproterenol-induced damage. Mechanistically, they propose that PARP16 regulates the nuclear translocation and transcriptional activity of NFAT1 through mono-ADP-ribosylation (MARylation), thereby linking this post-translational modification to hypertrophic and remodeling signaling in the heart. The conclusions rest …
Reviewer #2 (Public review):
In this study, the authors investigate the role of PARP16, an ER-resident mono-ADP-ribosyltransferase, in the heart. To address this, they generate a set of complementary mouse models: whole-body Parp16 knockout mice, constitutive and tamoxifen-inducible cardiomyocyte-specific knockout mice, and cardiomyocyte-specific transgenic mice overexpressing PARP16. Using these models, they show that loss of PARP16 causes pathological cardiac remodeling, whereas its overexpression protects the heart from isoproterenol-induced damage. Mechanistically, they propose that PARP16 regulates the nuclear translocation and transcriptional activity of NFAT1 through mono-ADP-ribosylation (MARylation), thereby linking this post-translational modification to hypertrophic and remodeling signaling in the heart. The conclusions rest on in vivo phenotyping, biochemical assays and immunofluorescence analyses.
Most of the conclusions are supported by the data, but some aspects of the biochemical assays, western blots and data analysis need to be clarified and improved.
Specific comments:
(1) Figure 1:
In Figure 1F, the authors describe a reorganization of α-actinin, but no quantification supports this conclusion; the phenotype should be quantified. The immunofluorescence images are not sufficiently clear and need to be improved. The organization of Figure 1J is misleading, and the transfection control should be separated from the ANP and α-actinin staining. The PARP16 immunofluorescence is not convincing: no clear difference is observed between the control in Figure 1F and the PARP16-overexpressing samples in Figure 1J. If the protein is tagged, an anti-tag antibody should be used to show overexpression. The catalogue number reported in the Methods for the PARP16 antibody is incorrect. In Figures 1G and 1K, the meaning of "−ve" and "+ve" is not explained. Moreover, the graphs lack error bars, and the number of experiments is not reported.
(2) Figure 7:
In Figure 7B, quantification of the blot should be included. Panels 7G and 7J report the same values for VIVIT-treated samples, and their representation in two separate graphs is misleading. The authors should merge them into a single graph including pre-treatment, vehicle and VIVIT-treated samples. In Figure 7K, the identity of p-NFAT1 is unclear: is the band at the same molecular weight as total NFAT1? No arrow is indicated in the raw data file, and no molecular weight markers are shown. If it comes from a different gel, was the phosphorylated form normalized to its own loading control? Why does NFAT1 run at 140 kDa here rather than at 110 kDa, as in all other panels? The quantification in 7L does not reflect the blot shown in Figure 7K.
(3) Figure 8:
The description of Figure 8 in the text is confusing. In Figure 8A, the results for PARP16 WT overexpression are misleading: why is the effect of PARP16 WT overexpression more pronounced upon silencing? The authors should discuss this point and include a control western blot showing effective knockdown and rescue of PARP16 protein upon overexpression. The level of PARP16 overexpression in Figure 8C is unexpectedly low, almost comparable to the non-transfected sample, and is therefore not convincing. Moreover, GAPDH and PARP16 migrate at almost the same molecular weight (about 36 kDa), yet the band indicated as PARP16 in the raw images is at a higher molecular weight than expected and than indicated in Figure 8C. The loss of the PARP16-NFAT1 interaction upon overexpression of PARP16 Y254A should be commented on in the text. Finally, no reference to panel 8D was found in the text.
(4) Supplementary data:
In lines 202-206, the authors state that "immunoblotting and gene expression analyses did not reveal marked alterations in the major UPR pathways in PARP16-deficient hearts (Fig. S1E-G)", and conclude that ER stress is absent. This conclusion is only partially supported. Gene expression of UPR targets is unchanged (S1G), but the western blot (S1E) and its quantification (S1F) do not support the same conclusion. PARP16 is important for PERK and IRE1 activation upon ER stress, and phosphorylation of eIF2α (p-eIF2α normalized to total eIF2α?) is significantly reduced in the PARP16 KO samples, suggesting an alteration of the PERK axis. To rule out defects in the IRE1 branch, XBP1 mRNA splicing should be evaluated by PCR. Since PARP16 loss could affect the stability of its substrates PERK and IRE1, measuring GRP78/BiP protein and mRNA levels would help assess cardiac UPR induction. Finally, the blot shows n=3 samples, while the quantification is based on n=4; why was the fourth sample excluded from the image in the raw data of Figure S1? Additional points: the font size for "110 kDa" should be corrected. Figures S2B and S2C show the same limitations reported for Figures 1F and 1K, respectively. Figure S3E is not discussed in the main text. This panel shows an HA-NFAT1 immunoprecipitation in the presence or absence of PARP16-FLAG, but the expression of HA-NFAT1 (input) and its immunoprecipitation (IP HA) are very limited. By contrast, the amount of co-immunoprecipitated PARP16-FLAG is abundant relative to the bait, even though its expression in the input is poor compared to the non-transfected samples. Collectively, this experiment is not convincing.
-
Reviewer #3 (Public review):
Summary:
This study investigates the role of PARP16 in pathological cardiac remodelling. Using multiple mouse models, the authors show that PARP16 deficiency promotes adverse cardiac remodelling and systolic dysfunction, whereas its overexpression exerts protective effects. The authors propose that PARP16 limits cardiac remodelling by inhibiting NFAT1 transcriptional activity through ADP-ribosylation.
Strengths:
The use of complementary genetic models, together with transcriptomic analyses and functional rescue experiments, provides substantial evidence for a protective role of PARP16 in cardiac homeostasis. The findings support the involvement of calcineurin-NFAT signalling and identify a potentially novel PARP16-NFAT1 regulatory axis.
Weaknesses:
The main limitation concerns the proposed molecular …
Reviewer #3 (Public review):
Summary:
This study investigates the role of PARP16 in pathological cardiac remodelling. Using multiple mouse models, the authors show that PARP16 deficiency promotes adverse cardiac remodelling and systolic dysfunction, whereas its overexpression exerts protective effects. The authors propose that PARP16 limits cardiac remodelling by inhibiting NFAT1 transcriptional activity through ADP-ribosylation.
Strengths:
The use of complementary genetic models, together with transcriptomic analyses and functional rescue experiments, provides substantial evidence for a protective role of PARP16 in cardiac homeostasis. The findings support the involvement of calcineurin-NFAT signalling and identify a potentially novel PARP16-NFAT1 regulatory axis.
Weaknesses:
The main limitation concerns the proposed molecular mechanism. Although the authors provide evidence of PARP16-NFAT1 association and identify candidate ADP-ribosylation sites, the causal link between modification of these residues and NFAT1 inhibition remains incompletely established. Moreover, the VIVIT rescue experiments support the involvement of NFAT signalling but do not demonstrate a specific role for NFAT1. Finally, the subcellular localization of the proposed interaction remains unclear, given the ER association of PARP16 and the nuclear activity of NFAT1. Clarifying these aspects would strengthen the mechanistic conclusions.
-
-
-
-
PARP16 protects against cardiac hypertrophic response by ADP-ribosylation-dependent inhibition of NFAT transcription factor https://www.biorxiv.org/content/10.64898/2026.03.30.715447v1
-
PARP16 protects against cardiac hypertrophic response by ADP-ribosylation-dependent inhibition of NFAT transcription factor https://www.biorxiv.org/content/10.64898/2026.03.30.715447v1
-